Identification of Proteomic Signatures in Chronic Obstructive Pulmonary Disease Emphysematous Phenotype

Shuang Bai1, Rui Ye1, Cuihong Wang1, Pengbo Sun1, Di Wang1, Yong Yue2, Huiying Wang2, Si Wu3, Miao Yu3, Shuhua Xi4*† and Li Zhao1*†

1Department of Pulmonary and Critical Care Medicine, Shengjing Hospital of China Medical University, Shenyang, China, 2Department of Radiology, Shengjing Hospital of China Medical University, Shenyang, China, 3Department of Biobank, Shengjing Hospital of China Medical University, Shenyang, China, 4Department of Environmental and Occupational Health, School of Public Health, China Medical University, Shenyang, China

Chronic obstructive pulmonary disease (COPD) is a highly heterogeneous disease. Emphysematous phenotype is the most common and critical phenotype, which is characterized by progressive lung destruction and poor prognosis. However, the underlying mechanism of this structural damage has not been completely elucidated. A total of 12 patients with COPD emphysematous phenotype (COPD-E) and nine patients with COPD non-emphysematous phenotype (COPD-NE) were enrolled to determine differences in differential abundant protein (DAP) expression between both groups. Quantitative tandem mass tag–based proteomics was performed on lung tissue samples of all patients. A total of 29 and 15 lung tissue samples from patients in COPD-E and COPD-NE groups, respectively, were used as the validation cohort to verify the proteomic analysis results using western blotting. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were conducted for DAPs. A total of 4,343 proteins were identified, of which 25 were upregulated and 11 were downregulated in the COPD-E group. GO and KEGG analyses showed that wound repair and retinol metabolism–related pathways play an essential role in the molecular mechanism of COPD emphysematous phenotype. Three proteins, namely, KRT17, DHRS9, and FMO3, were selected for validation. While KRT17 and DHRS9 were highly expressed in the lung tissue samples of the COPD-E group, FMO3 expression was not significantly different between both groups. In conclusion, KRT17 and DHRS9 are highly expressed in the lung tissue of patients with COPD emphysematous phenotype. Therefore, these proteins might involve in wound healing and retinol metabolism in patients with emphysematous phenotype and can be used as phenotype-specific markers.

Keywords: chronic obstructive pulmonary disease, emphysematous phenotype, proteomics, KRT17, DHRS9

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) emphysematous phenotype is characterized by lung tissue destruction and distal airspace over-inflation (Alford et al., 2010; Camp et al., 2014; Wang et al., 2018). In contrast to patients with other COPD phenotypes, those with emphysematous phenotype typically manifest symptoms such as severe dyspnea, decreased exercise tolerance, and physiological complications. Moreover, patients with emphysematous phenotype have a higher mortality than
those with non-emphysematous phenotype (Fan et al., 2014; Criner et al., 2018; Bai et al., 2020). Some emphysematous smokers do not exhibit airflow limitation (Oelsner et al., 2014), despite showing similar pathological features to those with COPD (Bai et al., 2020). Unfortunately, there are few biomarkers that could be useful to predict the emphysema phenotype in COPD patients. And pharmaceutical intervention to reverse lung destruction or inhibit pulmonary damage is not available for these patients (Vogelmeier et al., 2017; Janssen et al., 2019).

Low blood eosinophils, elevated plasmin–mediated degradation of cross-linked fibrin, and hypermethylation of microRNA-7 are regarded as the features of emphysematous phenotype (Papaioannou et al., 2017; Manon-Jensen et al., 2019; Rosas-Alonso et al., 2020), but their potential to serve as prognostic biomarkers needs further validation. Moreover, the underlying molecular mechanism of COPD emphysematous phenotype remains unclear. Besides, imbalances between proteases/antiproteases and oxidants/antioxidants, enhanced inflammatory response (Lan et al., 2019; Zeng et al., 2020), and dysfunctional tissue repair in the lung parenchyma and interstitium play an important role in the pathogenetic mechanisms of emphysema (Jiang et al., 2017; Belgacemi et al., 2020; Hu et al., 2020). However, the underlying mechanisms remain poorly understood.

Proteomics reflects proteins expression changes, which are occurring in organisms. It is an important tool to understand pathogenesis and identify disease biomarkers. Tandem mass tag (TMT) quantitative proteomics is a reliable approach to measure protein content, and it has been increasingly used to identify pathogenetic mechanisms and human disease biomarkers (Mertins et al., 2018; Dziekan et al., 2020; Wang et al., 2020). While most proteomic studies in patients with COPD have used bronchoalveolar lavage fluid (Tu et al., 2014), sputum (Titz et al., 2015), and blood (Sridhar et al., 2019), only a few have used lung tissue samples. Furthermore, as per our understanding, the studies that specifically addressed COPD emphysematous phenotype are not available. Since COPD is a highly heterogeneous disease, the proteomic analysis focused on its emphysematous phenotype has remarkable significance.

In this study, we conducted proteomic analysis of lung tissue samples using TMT quantitative proteomic techniques to identify key molecules and their underlying mechanisms in patients with COPD emphysematous phenotype.

**MATERIALS AND METHODS**

**Patients**

Patients with COPD were recruited based on the criteria previously described (Bai et al., 2020). In brief, the inclusion criteria were as follows: 40- to 80-year-old patients diagnosed with COPD, more than 10 pack-years of smoking history, preparing for chest surgery, and read and signed informed consent. Patients with other respiratory diseases, autoimmune diseases, or infections that occurred within 4 weeks before surgery were excluded. All enrolled patients were assigned to two groups: the COPD emphysematous phenotype (COPD-E) group and the COPD non-emphysematous phenotype (COPD-NE) group, according to the diagnosis of investigators and results of image analysis. Chest computed tomography (CT) scans revealed obvious emphysema in COPD-E patients and almost no emphysema in COPD-NE patients. The patients in both groups were matched for sex, age, and smoking history. The study protocol was approved by the Ethics Committee of Shengjing Hospital of China Medical University (Shenyang, China; Ethical no. 2016PS342K). For each patient included, written informed consent was obtained.

**CT Scanning**

Chest CT scans were obtained for all patients using Philips Brilliance iCT 256 (Philips, Surrey, United Kingdom), TOSHIBA Aquilion ONE (Toshiba, Tokyo, Japan), Siemens SOMATOM Definition Flash (Siemens, Forchheim, Germany), or GE Optima CT660 (GE, Milwaukee, WI, United States). All scans were obtained at a deep inspiratory breath hold. The following parameters were applied in the examination: tube voltage, 120 kV; tube current, 180 mA; and reconstruction matrix, 512 × 512. Two radiologists performed radiological measurements. The detailed CT acquisition parameters are shown in Supplementary Table S1.

**Emphysema Screening**

Chest CT scans of the patients were acquired from the CT workstation (Neusoft, Shenyang, China), and the image analyses were performed using Pulmonary Toolkit in Matlab (R2016a) (The MathWorks, Inc., Natick, MA, United States). The degree of emphysema was determined quantitatively according to our previous study (Bai et al., 2020). In brief, voxels with a CT value less than −950 HU were identified as the emphysematous area. The emphysema index was defined as the lung volume fraction of voxels with a CT value below −950 HU at a full inspiration (Camp et al., 2009; Coxson et al., 2014). The emphysema percentile density was defined as the 15th percentile lung density derived from the distribution histogram of whole lung CT voxel (Dirksen et al., 2009). The raw data of all CT images were entered into the analysis software, following which the results were obtained.

**Sample Preparation**

Samples were prepared as described previously (Sun et al., 2019; Bai et al., 2020). In brief, lung tissue samples were obtained as far as possible from the tumor (at least 5 cm from the boundary). Lung parenchyma, pulmonary vessels, and small airways were equal approximately in each sample. Each specimen was cleaned with normal saline and dried. The collected lung tissue samples were frozen with liquid nitrogen immediately and stored at −80°C until use.

The lung tissue samples were lysed using the SDT (4% SDS (w/v); 0.1 M DTT; 100 mM Tris-HCl, pH 7.6) lysis method. The BCA method was used to determine protein concentration. Every three tissue samples of COPD-NE patients were pooled together to form the three biological replicates in the COPD-NE group, and every four tissue samples of COPD-E patients were pooled
together to form the three biological replicates in the COPD-E group. The filter-aided proteome preparation method was used to perform protein collection (Wisniewski et al., 2009). In brief, lysates were mixed with 8 M urea in the filter unit of Microcon devices (Millipore, Bedford, MA, United States) and centrifuged to remove the low-molecular-weight material. Subsequently, 0.05 M iodoacetamide in 8 M urea was added to the concentrate followed by centrifugation. The resulting concentrate was diluted with 8 M urea and concentrated again. Finally, endoproteasein was added to digest proteins, and the digests were centrifuged to collect peptides. The concentration of peptide was measured at OD280. An equal amount of peptide was used from each sample, and all peptides were labeled using the TMT10 labeling kit (Thermo Fisher Scientific, Waltham, MA, United States) as described in the manufacturer’s instructions. Then, the labeled peptides were mixed, and the high-pH reversed-phase peptide fractionation kit was used to perform grading subsequently. Briefly, the fractionation column was equilibrated with acetonitrile and 0.1% trifluoroacetic acid, and the labeled peptides were loaded into the column. After adding pure water, the samples were centrifuged at a low speed for desalination treatment. Finally, the column-bound peptides were gradient-eluted with increasing concentrations of high-pH acetonitrile solutions. Each eluted peptide sample was dried in vacuum and reconstituted in 0.1% formic acid. The peptide concentration of each sample was measured at OD280.

**Liquid Chromatography-Tandem Mass Spectrometry Analysis**

A high-performance liquid chromatography liquid-phase system (Thermo Fisher Scientific, Waltham, MA, United States) was used to separate the graded samples passed consecutively through the loading and analytical columns at 300 nl/min. Subsequently, a Q Exactive mass spectrometer (Thermo Fisher Scientific, Waltham, MA, United States) was used to perform LC-MS/MS analysis. The following parameters were applied for detection: positive ion mode; the precursor ion scanning range was 300–1800 m/z; the first-order mass spectrum resolution was 70,000 at 200 m/z; the automatic gain control target was 1e6; maximum IT at 50 ms; and dynamic exclusion at 60 s. The collection method of peptide fragments’ mass-to-mass ratio was as follows: 20 fragment spectra (MS2 scans) were collected after each full scan; the MS2 activation type was high-energy collision dissociation; and the isolation window was 2 m/z. In addition, the secondary MS resolution was 35,000 at 200 m/z, with a normalized collision energy of 30 eV and 0.1% underfill.

**Protein Identification and Quantification**

Proteins were identified in the UniProt database using Mascot 2.2 and Proteome Discoverer 1.4 software. The selection criteria for the trusted peptides were as follows: FDR < 0.01; peptide mass of ±20 ppm; and fragment mass tolerance of 0.1 Da. Protein quantification was performed in accordance with only the unique peptides’ median of the protein. By calculating the relative expression ratio of the target protein to the reference protein for all samples in each group, the protein abundant differences between the two groups were compared. Finally, all peptide ratios were normalized using the median protein ratio.

**Bioinformatics Analysis**

Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were analyzed using Blast2GO and KEGG automatic annotation server software, respectively. Fisher’s exact test was used to compare the distribution of target proteins in the GO and KEGG pathways and perform enrichment analysis. Protein cluster analysis was conducted using the ComplexHeatmap R package (R version 3.4). The expression matrix of target proteins was normalized prior to the generation of the hierarchical cluster heat map. Protein interaction network analysis of target proteins was based on the STRING database and visualized with Cytoscape software (version 3.6.0). The overall scheme of TMT quantitative proteomics is shown in Figure 1.

**Western Blot Analysis**

Western blotting was performed according to our previous protocols (Bai et al., 2020). In brief, total protein extracts were prepared using RIPA lysis buffer, and the concentration of protein was estimated using the BCA method. In sodium dodecyl sulfate-polyacrylamide gel electrophoresis, equal amounts of denatured proteins were loaded. Each sample protein was transferred from gel to a polyvinylidene fluoride membrane, blocked with 5% non-fat milk, and incubated overnight with the primary antibody at 4°C. On the following day, secondary antibodies were added to incubate the membrane for 1 h. For chemiluminescence detection, protein bands were revealed using enhanced chemiluminescence reagent. The following primary antibodies were used: anti-KRT17 (ab51056) and anti-FMO3 (ab126711) from Abcam (Cambridge, Cambridgeshire, United Kingdom) and anti-DHRS9 and anti-GAPDH from Proteintech (Chicago, IL, United States).

**Statistical Analysis**

All statistical analyses were performed using GraphPad Prism 7 (GraphPad, La Jolla, CA, United States), except for bioinformatics analysis. Bioinformatics-related statistical software and methods are described in Bioinformatics Analysis. Student’s t-test was used to compare means between two groups of normally distributed data. For data with non-normal distribution, the Mann–Whitney U test was used. The comparison of two groups of categorical variable data was analyzed by Fisher’s exact probability. Continuous variables are expressed as the mean ± standard error of mean. Linear regression analysis was conducted for regression and correlation analyses. p < 0.05 was regarded as statistically significant.

**RESULTS**

**Demographic and Radiological Features**

In total, 16 patients in the COPD-NE group and 29 patients in the COPD-E group were recruited between September 2016 and June 2019. Lung tissue samples of 9 patients in the COPD-NE group and 12 patients in the COPD-E group were used for proteomic
These 21 lung tissues were collected between September 2016 and March 2018 and defined as the discovery cohort. Until June 2019, all samples had been collected and defined as the validation cohort. The validation cohort consisted of 15 COPD-NE lung tissues and 29 COPD-E lung tissues, of which 8 COPD-NE specimens and 12 COPD-E specimens were involved in the discovery cohort. For general features and pulmonary function parameters, there were no significant differences between both groups in the discovery and validation cohorts. However, both cohorts predominantly consisted of male patients, and the discovery cohort consisted of only male patients. In the validation cohort, patients of the COPD-E group had a longer smoking history than those in the COPD-NE group. However, there were no significant differences in pack-years between the two groups. One patient in the discovery cohort and four in the validation cohort did not have pulmonary function test results (Table 1, Table 2).

In the discovery cohort, patients in the COPD-E group showed a higher emphysema index (2.94 ± 1.12 vs. 1.15 ± 2.78, p = 0.02) and lower emphysema percentile density...
Protein Identification and Differential Abundant Protein Screening

A total of 31,479 peptides, including 27,157 unique peptides, were identified by mass spectrometry, and 4,343 proteins were finally identified. All identified proteins and related information are shown in Supplementary Table S2. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via the iProX partner repository with the dataset identifier PXD023900 (Ma et al., 2019). DAPs were identified using the following screening criteria: COPD-E/COPD-NE ratio greater than 1.2-fold (upregulation greater than 1.2-fold or downregulation less than 0.83-fold) and \( p < 0.05 \). A total of 36 DAPs were identified, of which 25 were upregulated and 11 were downregulated. The type I cytoskeletal 17 (KRT17) protein expression in the COPD-E group was 1.54-fold higher than that in the COPD-NE group, as the protein with the most obvious differences between the two groups. All DAPs are listed in Table 4, and a volcano plot showing the distribution of DAPs is illustrated in Figure 2A. Hierarchical cluster analysis showed that the samples were clustered into two categories, which were the same groups as the original groups. The clustering results are shown in Figure 2B.

Functional Enrichment and Protein–Protein Interaction Network of DAPs

GO functional annotation and enrichment analysis was performed for all DAPs, the results of which are shown in Supplementary Table S3. The GO terms were ordered according to the \( p \) value, and the top 20 enriched GO terms included eight terms in the biological pathway, six terms in the molecular function, and six terms in the cellular component. The biological pathway was mainly related to tissue refactoring and wound healing, including regulation of response to wound, regulation of wound healing, pathways that downregulate wound-related response and healing, response to external stimuli, and defense response. The molecular function was predominantly related to protein binding; protein–lipid complex binding and lipoprotein particle binding had the highest enrichment factor (0.23). For the cellular component, most DAPs were found in the extracellular matrix and some in organelles. Enrichment analysis results of the top 20 enriched GO terms with smallest \( p \) values are displayed in Figure 3A. GO terms at level 2 are on higher positions in the hierarchy of GO terms. Level 2 GO terms describe the properties of proteins more comprehensively, and all of the level 2 GO terms involved in GO enrichment are shown in Figure 3B. The metabolic process may occupy an important position in emphysematous phenotype–related biological pathways; besides, growth, cell proliferation, and developmental...
process were also involved. Binding was the most predominant molecular function of DAPs. In addition to the extracellular matrix, organelles may be the portion that DAPs were mainly distributed in.

To understand the mechanisms and signaling pathways that DAPs may participate in the pathogenesis of COPD emphysematous phenotype, we performed KEGG pathway annotation and enrichment analysis of all DAPs; the specific results are shown in Supplementary Table S4. KEGG enrichment analysis showed that most DAPs were involved in metabolic and inflammatory pathways, including nitrogen metabolism, PPAR signaling, NF-κB signaling, and cholesterol metabolism. All KEGG terms with p values less than 0.05 are shown in Figure 4A and ordered according to the p value. The top 20 KEGG terms with largest enriched protein numbers are shown in Figure 4B.

PPI network analysis was used to analyze the interaction between DAPs. As shown in Figure 5, 16 out of 36 DAPs had interaction nodes. Apolipoprotein E is the DAP that has most interactions with other DAPs, which indicates it may serve as a key molecule in the mechanism of emphysema. Besides, serum amyloid P-component, various chains of fibrinogen, and different subcomponent subunits of the complement interact with each other. These DAPs were related to the pathways in the results of GO and KEGG enrichment analyses. Therefore, these interactions may play roles in the pathogenesis of emphysematous phenotype, as well.

Validation and Functional Annotation of DAPs

The expression of KRT17, dehydrogenase/reductase short-chain alcohol dehydrogenase/reductase (SDR) family member 9 (DHR9), and dimethylamine monoxygenase 3 (FMO3) was determined. Each lung tissue sample obtained from a subject was used as an independent sample in western blot. Western blotting results showing the expression of these proteins in the lung tissue samples of the validation cohort are shown in Figure 6. The protein expression of KRT17 (COPD-NE, n = 13, COPD-E, n =

### Table 4: Differential abundant proteins in the COPD-E and COPE-NE groups.

| Accession | Description                              | Gene name       | COPD-E/COPD-NE ratio | p value  |
|-----------|------------------------------------------|-----------------|----------------------|----------|
| Q04695    | Keratin, type I cytoskeletal 17          | KRT17           | 1.54                 | 0.037*   |
| P02745    | Complement C1q subcomponent subunit A    | C1QA            | 1.48                 | <0.001***|
| Q8BXD5    | N-acetylneuraminic lyase                 | NPL             | 1.45                 | 0.040*   |
| P02794    | Ferritin heavy chain                     | FTH1            | 1.38                 | 0.019*   |
| P48061    | Stromal cell-derived factor 1            | CXCL12          | 1.38                 | 0.015*   |
| P39900    | Macrophage metalloelastase               | MMP12           | 1.35                 | 0.024*   |
| P02747    | Complement C1q subcomponent subunit C    | C1QC            | 1.34                 | 0.031*   |
| P0D0X8    | Immunoglobulin lambda-1 light chain      | —               | 1.33                 | 0.039*   |
| P02679    | Fibrinogen gamma chain                   | FGG             | 1.32                 | <0.001***|
| P02746    | Complement C1q subcomponent subunit B    | C1QB            | 1.31                 | 0.012*   |
| Q9NP78    | ATP-binding cassette sub-family B member 9| ABCS9           | 1.30                 | 0.024*   |
| Q8TED4    | Glucose-6-phosphate exchange SLC37A2     | SLC37A2         | 1.28                 | 0.021*   |
| P0C0L4    | Complement C4-A                          | C4A             | 1.28                 | 0.020*   |
| P02671    | Fibrinogen alpha chain                   | FGA             | 1.27                 | 0.003***  |
| M0R2J8    | Doublecortin domain-containing protein 1 | DCDC1           | 1.26                 | <0.001***|
| P02675    | Fibrinogen beta chain                    | FGB             | 1.26                 | 0.001**  |
| Q9BPW9    | Dehydrogenase/reductase SDR family member 9| DHR9            | 1.25                 | 0.005**  |
| P02649    | Apolipoprotein E                         | APOE            | 1.24                 | 0.041*   |
| P31513    | Dimethylamine monoxygenase [N-oxide-forming] 3 | FMO3            | 1.23                 | 0.022*   |
| P18428    | Lipopolysaccharide-binding protein        | LBP             | 1.23                 | 0.028*   |
| Q8BXN1    | Asporin                                  | ASPN            | 1.23                 | 0.038*   |
| P02743    | Serum amyloid P-component                 | APCS            | 1.22                 | 0.023*   |
| Q576F0    | DDB1- and CUL4-associated factor 12       | DCAF12          | 1.21                 | 0.004***  |
| P04003    | C4b-binding protein alpha chain          | C4BPA           | 1.21                 | 0.036*   |
| P35542    | Serum amyloid A-4 protein                 | SAA4            | 1.20                 | 0.025*   |
| Q96D46    | 60S ribosomal export protein NMD3        | NMD3            | 0.83                 | 0.011*   |
| P3764     | Protein S100-A3                          | S100A3          | 0.83                 | 0.049*   |
| P31415    | Calsequestrin-1                          | CASQ1           | 0.82                 | 0.007**  |
| P28906    | Hematopoietic progenitor cell antigen CD34| CD34            | 0.81                 | 0.016*   |
| P15090    | Fatty acid-binding protein, adipocyte     | FABP4           | 0.81                 | 0.033*   |
| P43155    | Carnitine O-acetyltransferase             | CRAT            | 0.80                 | 0.032*   |
| P16671    | Platelet glycoprotein 4                   | CD36            | 0.79                 | 0.008*   |
| Q96B54    | Zinc finger protein 428                  | ZNF428          | 0.78                 | 0.017*   |
| P22748    | Carbonic anhydrase 4                      | CA4             | 0.78                 | 0.014*   |
| P17152    | Transmembrane protein 11, mitochondrial   | TEMEM11         | 0.76                 | 0.018*   |
| P30486    | HLA class I histocompatibility antigen, B-4 alpha chain | HLA-B       | 0.76                 | 0.014*   |

*p < 0.05, **p < 0.01, ***p < 0.001.
24; \( p < 0.01 \) and DHRS9 (COPD-NE, \( n = 13 \), COPD-E, \( n = 24 \); \( p < 0.01 \)) in the COPD-E group was higher than that in the COPD-NE group. However, the FMO3 expression was not significantly different between both groups. Western blotting results of all lung tissue samples are shown in Supplementary Figure S1.

The annotation results showed that KRT17 acts as a cytoskeletal protein and takes part in the process of cell growth and development, while DHRS9 participates in multiple metabolic pathways, such as retinol and steroid hormone biosynthesis (Table 5).

**FIGURE 2** | Quantification and hierarchical clustering of differential abundant proteins (DAPs) in COPD emphysematous phenotype. (A) Volcano plot of DAPs. (B) Hierarchical clustering heat map of DAPs.
DISCUSSION

Patients with COPD emphysematous phenotype account for a considerable portion in clinics. Patients with this phenotype manifest progressive destruction of lung tissue and poor response to current pharmaceutical interventions of COPD (Janssen et al., 2019). With an aim of exploring the specific mechanism underlying the development of this phenotype, the proteome of lung tissues from patients with COPD emphysematous phenotype was studied using TMT quantitative proteomics. A total of 4,343 proteins were identified, out of which 36 were DAPs. Of these, 25 DAPs were upregulated and 11 DAPs were downregulated. This result was comparable with that of other proteomic analyses on lung tissue (Sun et al., 2019; Wu et al., 2020). Functional enrichment analysis of DAPs showed that tissue repair and cell

![Gene ontology (GO) enrichment analysis of differential abundant proteins.](image)

**FIGURE 3** Gene ontology (GO) enrichment analysis of differential abundant proteins. (A) Top 20 enriched terms with smallest p values in GO enrichment analysis. (B) All level 2 GO terms involved in GO enrichment analysis.
proliferation and development were primarily related to the pathogenesis of emphysematous phenotype, in addition to inflammatory response, collagen disruption, and other well-recognized mechanisms in emphysema (Lan et al., 2019). Moreover, cholesterol-related, retinol-related, and other lipid-related metabolic pathways were enriched in KEGG pathway analysis. These results suggested that the impaired ability to repair injured tissue and lipid metabolism disorder might play an essential role in the development of prominent lung tissue destruction in COPD emphysematous phenotype. The differential expression of KRT17 and DHRS9 was validated in the lung tissue samples of patients with COPD emphysematous phenotype. Therefore, KRT17 and DHRS9 might affect the pathogenesis of COPD emphysematous phenotype by regulating tissue repair and lipid metabolism and act as phenotype-specific proteomic signatures.

Tissue repair is an essential process for all organisms to protect and maintain the normal structure and function. As structural destruction and collagen fibril disorder are prominently observed in patients with COPD emphysematous phenotype, the impaired ability to repair lung parenchymal and interstitial cells might play a significant role in its pathogenesis (Hu et al., 2020). The WNT/β-catenin pathway is a classical pathway involved in lung growth and development, and cell proliferation and differentiation (Königshoff and Eickelberg, 2010). Downregulation of this pathway will result in the retardation of tissue repair (Kneidinger et al., 2011; Uhl et al., 2015). Under normal conditions, WNT activates the JNK pathway by forming a complex with small G-proteins to promote cytoskeletal rearrangement during embryonic development (Wiggan and Hamel, 2002; Zhang et al., 2018). Moreover, the canonical WNT signaling pathway promotes the proliferation of type II alveolar epithelial cells (AECIIs) and trans-differentiation of AECIIs to type I alveolar epithelial cells (AECIs) that replenish injured ones in the damaged process of emphysema. In contrast, the non-canonical WNT signaling pathway inhibits proliferation.

**Figure 4 | Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of differential abundant proteins.** (A) Enriched terms in KEGG enrichment analysis with p values less than 0.05. (B) Top 20 KEGG terms with largest enriched protein numbers in KEGG enrichment results.
KRT17 is an important component of cytoskeleton. Functional annotation of DAPs showed that KRT17 participates in cell growth and development and cytoskeletal composition. Therefore, KRT17 has a potential to serve as an important target of the WNT/\(\beta\)-catenin signaling pathway. Both canonical and non-canonical WNT signaling pathways may rearrange or affect the abundance of cytoskeletal component—KRT17, resulting in the severe tissue destruction in patients with COPD emphysematous phenotype. Some studies have confirmed that the expression of cyclin D1, MMP7, c-Myc, and other vital targets of the WNT/\(\beta\)-catenin pathway is increased in KRT17-overexpressing cells (Wang et al., 2019). However, the mechanism through which canonical and non-canonical WNT signaling pathways interact with KRT17 warrants further studies, and the specific roles of KRT17 in the development of COPD and emphysema are still to be explored.

Retinoic acid is synthesized from retinol, and it regulates lung development and alveolar formation in the human body. Some studies have shown that retinoic acid can inhibit the activation of YAP signaling and epithelial–mesenchymal FGF signaling pathways, which promotes the proliferation and inhibits the differentiation of alveolar epithelial cells (Ng-Blichfeldt et al., 2018). In addition, retinoic acid can downregulate pro-apoptotic

### TABLE 5 | Annotation of KRT17 and DHRS9.

| Accession | Gene name | ID | Annotation term |
|-----------|-----------|----|----------------|
| Q04695    | KRT17     | GO:00070268 | BP: cornification |
|           |           | GO:0008544  | BP: epidermis development |
|           |           | GO:0031069  | BP: hair follicle morphogenesis |
|           |           | GO:0045109  | BP: intermediate filament organization |
|           |           | GO:0051424  | BP: keratinization |
|           |           | GO:0030307  | BP: positive regulation of cell growth |
|           |           | GO:0051708  | BP: positive regulation of hair follicle development |
|           |           | GO:0045727  | BP: positive regulation of translation |
|           |           | GO:0007165  | BP: signal transduction |
|           |           | GO:0071944  | CC: cell periphery |
|           |           | GO:0005829  | CC: cytosol |
|           |           | GO:0070062  | CC: extracellular exosome |
|           |           | GO:0005882  | CC: intermediate filament |
|           |           | GO:0045111  | CC: intermediate filament cytoskeleton |
|           |           | GO:0042289  | MF: MHC class II protein binding |
|           |           | GO:0032395  | MF: MHC class II receptor activity |
|           |           | GO:0005200  | MF: structural constituent of cytoskeleton |
|           |           | hsa05150    | Staphylococcus aureus infection |
| Q9BPW9    | DHRS9     | GO:0042904  | BP: 9-cis-retinoic acid biosynthetic process |
|           |           | GO:0008209  | BP: androgen metabolic process |
|           |           | GO:0030865  | BP: epithelial cell differentiation |
|           |           | GO:0042248  | BP: progesterone metabolic process |
|           |           | GO:0004572  | BP: retinol metabolic process |
|           |           | GO:0005789  | CC: endoplasmic reticulum membrane |
|           |           | GO:0030176  | CC: integral component of endoplasmic reticulum membrane |
|           |           | GO:0040422  | MF: alcohol dehydrogenase (NAD) activity |
|           |           | GO:0047044  | MF: androstan-3-alpha,17-beta-diol dehydrogenase activity |
|           |           | GO:0047023  | MF: androsterone dehydrogenase activity |
|           |           | GO:0016854  | MF: racemase and epimerase activity |
|           |           | GO:0004745  | MF: retinol dehydrogenase activity |
|           |           | GO:0047035  | MF: testosterone dehydrogenase (NAD+) activity |
|           |           | hsa000830   | retinol metabolism |

**BP**: biological pathway; **CC**: cellular component; **MF**: molecular function.

### FIGURE 5 | Protein–protein interaction (PPI) network of differential abundant proteins.
genes and inhibit the apoptosis of alveolar epithelial cells (Chatterjee and Chatterji, 2017). Therefore, the functional enrichment of DAPs in cholesterol and retinol metabolism in this study suggests aberrant proliferation and differentiation caused by impaired lipid metabolism. DHRS9 is a member of the SDR family. Crosstalk between DHRS9 and retinaldehyde dehydrogenase 1 (Raldh1) exerts important regulatory functions in the synthesis of retinoic acid. Unlike other members of the SDR family (e.g., Rdh10 and Rdh2), DHRS9 knockdown increased retinoic acid synthesis in RALDH1-overexpressing cells (Wang et al., 2011). Combined with the results of functional annotation and enrichment, DHRS9 can modulate the synthesis of retinoic acid, which in turn regulates the proliferation and differentiation of alveolar epithelial cells (Ng-Blichfeldt et al., 2018). Furthermore, clinical studies have confirmed that DHRS9 can regulate inflammation (Morichika et al., 2019) as well as the balance between MMP9 and TIMP1 (Mao et al., 2003) in cells. These results suggest that DHRS9 is predominantly involved in the pathogenic mechanism of emphysema in patients with COPD emphysematous phenotype, but specific molecular mechanisms are still unclear and remain to be explored.

Serum (Sridhar et al., 2019), expectorated sputum (Titz et al., 2015), and bronchoalveolar lavage fluid (Tu et al. 2014) samples have been used in previous proteomic studies to analyze the COPD-related proteome. However, the number of detected DAPs was relatively small and easily influenced by a systemic disease. Lung tissue is the direct affected site of COPD emphysematous phenotype. Therefore, lung tissue samples are the most suitable to identify key molecules involved in the mechanism underlying emphysema pathogenesis. To the best of our knowledge, this is the first proteomic analysis that focuses on emphysematous phenotype, to detect the specific DAPs in this phenotype.

A total of 36 DAPs were identified in lung tissue samples from patients in the COPD emphysematous phenotype group. Of these, 25 DAPs were upregulated and 11 DAPs were downregulated. KRT17 and DHRS9 were found to take part in the pathogenesis of emphysema. Moreover, wound repair and retinol metabolism may be the processes they participated. Therefore, KRT17 and DHRS9 can be used as phenotype-specific proteomic signatures in patients with COPD emphysematous phenotype.

**CONCLUSION**

The original contributions presented in the study are publicly available. This data can be found here: ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org), dataset identifier: PXD023900.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are publicly available. This data can be found here: ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org), dataset identifier: PXD023900.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Ethics Committee of Shengjing Hospital of China Medical University (Shenyang, China; Ethical no. 2016PS342K). The patients/participants provided their written informed consent to participate in this study.
AUTHOR CONTRIBUTIONS

SB, SX and LZ substantially contributed to the conception and design of the manuscript. SB, RY, CW, PS, DW, YY, HW, SW, MY, SX and LZ contributed to the acquisition, analysis, and interpretation of data. SB, SX and LZ drafted the article, and SB, RY, CW, PS, DW, YY, HW, SW, MY, SX and LZ revised it critically and substantially. SB, RY, CW, PS, DW, YY, HW, SW, MY, SX and LZ approved the final version and accepted accountability for all aspects of the study. Corresponding authors SX and LZ contributed equally to this study.

REFERENCES

Alford, S. K., van Beek, E. J. R., McLennan, G., and Hoffman, E. A. (2010). Heterogeneity of Pulmonary Perfusion as a Mechanistic Image-Based Phenotype in Emphysema Susceptible Smokers. Proc. Natl. Acad. Sci. 107 (16), 7485–7490. doi:10.1073/pnas.0913880107

Bai, S., Ye, R., Wang, C., Sun, P., and Zhao, L. (2020). Comparative Analysis of Critically and Substantially. SB, RY, CW, PS, DW, YY, HW, SW, MY, SX and LZ approved the final version and accepted accountability for all aspects of the study. Corresponding authors SX and LZ contributed equally to this study.

ACKNOWLEDGEMENT

The authors would like to thank the Biological Sample Library of Shengjing Hospital for help of getting tissue samples.

SUPPLEMENTARY MATERIAL

The Supplemental Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmolb.2021.650604/full#supplementary-material
Skronska-Wasek, W., Mutze, K., Baarsma, H. A., Bracke, K. R., Alsafadi, H. N., Lehmann, M., et al. (2017). Reduced Frizzled Receptor 4 Expression Prevents WNT/β-Catenin-driven Alveolar Lung Repair in Chronic Obstructive Pulmonary Disease. *Am. J. Respir. Crit. Care Med.* 196 (2), 172–185. doi:10.1164/rcmm.201605-0904OC

Sridhar, S., Liu, H., Pham, T.-H., Damera, G., and Newbold, P. (2019). Modulation of Blood Inflammatory Markers by Benralizumab in Patients with Eosinophilic Airway Diseases. *Respir. Res.* 20 (1), 14. doi:10.1186/s12931-018-0968-8

Sun, P., Ye, R., Wang, C., Bai, S., and Zhao, L. (2019). Identification of Proteomic Signatures Associated with COPD Frequent Exacerbators. *Life Sci.* 230, 1–9. doi:10.1016/j.lfs.2019.05.047

Titz, B., Sewer, A., Schneider, T., Elamin, A., Martin, F., Dijon, S., et al. (2015). Alterations in the Sputum Proteome and Transcriptome in Smokers and Early-Stage COPD Subjects. *J. Proteomics* 128, 306–320. doi:10.1016/j.jprot.2015.08.009

Tu, C., Mammen, M. J., Li, J., Shen, X., Jiang, X., Hu, Q., et al. (2014). Large-scale, Ion-Current-Based Proteomics Investigation of Bronchoalveolar Lavage Fluid in Chronic Obstructive Pulmonary Disease Patients. *J. Proteome Res.* 13 (2), 627–639. doi:10.1021/pr4007602

Uhl, F. E., Vierkotten, S., Wagner, D. E., Burgstaller, G., Costa, R., Koch, I., et al. (2015). Preclinical Validation and Imaging of Wnt-Induced Repair in Human 3D Lung Tissue Cultures. *Eur. Respir. J.* 46 (4), 1150–1166. doi:10.1183/09031936.00183214

Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., et al. (2017). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. *Am. J. Respir. Crit. Care Med.* 195 (5), 557–582. doi:10.1164/rccm.201701-0218PP

Wang, C., de Mochel, N. S. R., Christenson, S. A., Cassandras, M., Moon, R., Brumwell, A. N., et al. (2018). Expansion of Hedgehog Disrupts Mesenchymal Identity and Induces Emphysema Phenotype. *J. Clin. Invest.* 128 (10), 4343–4358. doi:10.1172/jci99435

Zhang, P., Hu, C., Li, Y., Wang, Y., Gao, L., Lu, K., et al. (2018). Vangl2 Is Essential for Myocardial Remodeling Activated by Wnt/JNK Signaling. *Exp. Cell Res.* 365 (1), 33–45. doi:10.1016/j.yexcr.2018.02.012

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.